Federal regulators have granted fast-track review status of several uses for an experimental antibiotic drug developed by Cubist Pharmaceuticals Inc.
The Lexington company said it got fast-track status from the Food and Drug Administration for ceftolozane/tazobactam, also known as CXA-201, in treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, along with complicated urinary tract infections.
In February, the FDA granted fast-track status for CXA-201 in treating complex intra-abdominal infections.
If the drug is approved under the priority review, Cubist will get a five-year extension of exclusivity under an antibiotics incentive law signed by President Obama last year.
Robert WeismanRobert Weisman can be reached at email@example.com. Follow him on Twitter @GlobeRobW.